<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793817</url>
  </required_header>
  <id_info>
    <org_study_id>KPI-121-C-005</org_study_id>
    <nct_id>NCT02793817</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain</brief_title>
  <official_title>A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kala Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kala Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0%
      ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, double-masked, randomized, placebo-controlled,
      parallel-group study designed to evaluate the efficacy and safety of KPI-121 1.0% ophthalmic
      suspension versus placebo in subjects who require treatment of postoperative anterior ocular
      inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Resolution of Anterior Chamber (AC) Cells at Day 8</measure>
    <time_frame>Visit 5 (Day 8) maintained through Visit 6 (Day 15)</time_frame>
    <description>Number and percentage of subjects with complete resolution of AC cells in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Resolution of Ocular Pain at Day 8</measure>
    <time_frame>Visit 5 (Day 8) maintained through Visit 6 (Day 15)</time_frame>
    <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Resolution of Ocular Pain at Day 4</measure>
    <time_frame>Visit 4 (Day 4) maintained through Visit 6 (Day 15)</time_frame>
    <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Resolution of Anterior Chamber (AC) Flare at Day 4</measure>
    <time_frame>Visit 4 (Day 4) maintained through Visit 6 (Day 15)</time_frame>
    <description>Number and percentage of subjects with complete resolution of AC flare in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC flare based on the following scale wherein higher scores indicate a higher degree of flare present and a decrease across time indicates the condition is getting better.
Anterior Chamber Flare 0 = None
= Mild (trace to clearly noticeable, visible)
= Moderate (without plastic aqueous humor)
= Marked (with plastic aqueous humor)
= Severe (with fibrin deposits and/or clots)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 4</measure>
    <time_frame>Visit 1 (Baseline) and Visit 4 (Day 4)</time_frame>
    <description>The difference in mean changes from BL in AC cell count grade at Day 4 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Post Surgical Ocular Inflammation and Pain</condition>
  <arm_group>
    <arm_group_label>KPI-121 1.0% Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dosed BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of KPI-121 Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dosed BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPI-121 1% Ophthalmic Suspension dosed BID</intervention_name>
    <arm_group_label>KPI-121 1.0% Ophthalmic Suspension</arm_group_label>
    <other_name>Loteprednol etabonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of KPI-121 Ophthalmic Suspension dosed BID</intervention_name>
    <arm_group_label>Vehicle of KPI-121 Ophthalmic Suspension</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Candidates for routine, uncomplicated cataract surgery

        In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of
        at least 20/200 in study eye.

        Exclusion Criteria:

          -  Known hypersensitivity/contraindication to study product(s) or components.

          -  History of glaucoma, intraocular pressure (IOP) &gt;21 mmHg at the screening or
             randomization visits, or being treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance;
             severe/serious systemic disease or uncontrolled medical condition that in judgment of
             Investigator could confound study assessments or limit compliance; or have been
             exposed to an investigational drug within the 30 days prior to screening or 18 days
             following surgery.

          -  In the opinion of Investigator or study coordinator, be unwilling or unable to comply
             with study protocol or unable to successfully instill eye drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Eye Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of CA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Ophthalmology</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Research Institute</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LoBue Laser and Eye Medical Center</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pendleton Eye Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates, Inc.</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arch Health Partners</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martel Eye Medical Group</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shasta Eye Medical Group, Inc</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center of Northern Colorado, PC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shettle Eye Research, Inc</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants, Ltd.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksoneye, S. C.</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Eye Care</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, PA</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care, Ltd. / Vision Research Institute, LLC</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abrams Eye Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Eye</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roseburg Research Associates, LLC</name>
      <address>
        <city>Roseburg</city>
        <state>Oregon</state>
        <zip>97471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Cataract &amp; Laser Center</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye, PA / Keystone Research, Ltd</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cataract &amp; Glaucoma Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kozlovsky Delay &amp; Winter Eye Consultants, LLC Corona Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <results_first_submitted>October 25, 2018</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2019</results_first_posted>
  <disposition_first_submitted>July 11, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 12, 2018</disposition_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postsurgical</keyword>
  <keyword>postoperative</keyword>
  <keyword>ocular</keyword>
  <keyword>cataract</keyword>
  <keyword>inflammation</keyword>
  <keyword>pain</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02793817/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02793817/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>KPI-121 1.0% Ophthalmic Suspension</title>
          <description>dosed BID
KPI-121 1% Ophthalmic Suspension dosed BID</description>
        </group>
        <group group_id="P2">
          <title>Vehicle of KPI-121 Ophthalmic Suspension</title>
          <description>dosed BID
Vehicle of KPI-121 Ophthalmic Suspension dosed BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KPI-121 1.0% Ophthalmic Suspension</title>
          <description>dosed BID
KPI-121 1% Ophthalmic Suspension dosed BID</description>
        </group>
        <group group_id="B2">
          <title>Vehicle of KPI-121 Ophthalmic Suspension</title>
          <description>dosed BID
Vehicle of KPI-121 Ophthalmic Suspension dosed BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="261"/>
            <count group_id="B2" value="259"/>
            <count group_id="B3" value="520"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" lower_limit="38" upper_limit="89"/>
                    <measurement group_id="B2" value="69.3" lower_limit="40" upper_limit="90"/>
                    <measurement group_id="B3" value="68.4" lower_limit="38" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="413"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Resolution of Anterior Chamber (AC) Cells at Day 8</title>
        <description>Number and percentage of subjects with complete resolution of AC cells in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
        <time_frame>Visit 5 (Day 8) maintained through Visit 6 (Day 15)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Resolution of Anterior Chamber (AC) Cells at Day 8</title>
          <description>Number and percentage of subjects with complete resolution of AC cells in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-values were based on 2-sided chi-squared tests (unadjusted) wherein the a priori significance level was 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0105</p_value>
            <p_value_desc>To account for multiplicity, a step-down testing procedure was applied, whereby inference for a test in the pre-defined hierarchy was dependent upon statistical significance having been demonstrated for the previous test in the hierarchy.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without adjustment for any covariates</method_desc>
            <param_type>Difference in percentage of responders</param_type>
            <param_value>8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for % of responders and is expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Resolution of Ocular Pain at Day 8</title>
        <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
        <time_frame>Visit 5 (Day 8) maintained through Visit 6 (Day 15)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Resolution of Ocular Pain at Day 8</title>
          <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-values were based on 2-sided chi-squared test (unadjusted), wherein a priori significance level was 0.05</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiplicity, a step-down closed testing procedure was applied, whereby inference for a test in the pre-defined hierarchy was dependent upon statistical significance having been demonstrated for the previous test in the hierarchy.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without adjustment for any covariates</method_desc>
            <param_type>Difference in percentage of responders</param_type>
            <param_value>20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.6</ci_lower_limit>
            <ci_upper_limit>28.4</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for % of responders and is expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Resolution of Ocular Pain at Day 4</title>
        <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
        <time_frame>Visit 4 (Day 4) maintained through Visit 6 (Day 15)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Resolution of Ocular Pain at Day 4</title>
          <description>Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.
The following scoring scale was used for ocular pain:
0 = None
= Minimal
= Mild
= Moderate
= Moderately Severe
= Severe</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on a 2-sided chi-squared test (unadjusted) wherein the a priori significance level was 0.0167 for each secondary endpoint. Overall alpha for all secondary endpoints was controlled at 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without adjustment for any covariates</method_desc>
            <param_type>Difference in percentage of responders</param_type>
            <param_value>17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.1</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for % of responders and is expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Resolution of Anterior Chamber (AC) Flare at Day 4</title>
        <description>Number and percentage of subjects with complete resolution of AC flare in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC flare based on the following scale wherein higher scores indicate a higher degree of flare present and a decrease across time indicates the condition is getting better.
Anterior Chamber Flare 0 = None
= Mild (trace to clearly noticeable, visible)
= Moderate (without plastic aqueous humor)
= Marked (with plastic aqueous humor)
= Severe (with fibrin deposits and/or clots)</description>
        <time_frame>Visit 4 (Day 4) maintained through Visit 6 (Day 15)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Resolution of Anterior Chamber (AC) Flare at Day 4</title>
          <description>Number and percentage of subjects with complete resolution of AC flare in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC flare based on the following scale wherein higher scores indicate a higher degree of flare present and a decrease across time indicates the condition is getting better.
Anterior Chamber Flare 0 = None
= Mild (trace to clearly noticeable, visible)
= Moderate (without plastic aqueous humor)
= Marked (with plastic aqueous humor)
= Severe (with fibrin deposits and/or clots)</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on a 2-sided chi-squared test (unadjusted) wherein the a priori significance level was 0.0167 for each secondary endpoint. Overall alpha for all secondary endpoints was controlled at 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without adjustment for any covariates</method_desc>
            <param_type>Difference in percentage of responders</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.0</ci_lower_limit>
            <ci_upper_limit>26.9</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for % of responders and is expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 4</title>
        <description>The difference in mean changes from BL in AC cell count grade at Day 4 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
        <time_frame>Visit 1 (Baseline) and Visit 4 (Day 4)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 4</title>
          <description>The difference in mean changes from BL in AC cell count grade at Day 4 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.84"/>
                    <measurement group_id="O2" value="-0.5" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a 2-sided chi-squared test (unadjusted) wherein the a priori significance level was 0.0167 for each secondary endpoint. Overall alpha for all secondary endpoints was controlled at 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Chi-squared</method>
            <method_desc>Without adjustment for any covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for change from BL.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 8</title>
        <description>The difference in mean changes from BL in AC cell count grade at Day 8 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
        <time_frame>Visit 1 (Baseline) and Visit 5 (Day 8)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 8</title>
          <description>The difference in mean changes from BL in AC cell count grade at Day 8 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.90"/>
                    <measurement group_id="O2" value="-1.0" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-values have no inferential value for post hoc evaluations.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without any adjustment for covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference in change from BL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 15</title>
        <description>The difference in mean changes from BL in AC cell count grade at Day 15 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
        <time_frame>Visit 1 (Baseline) and Visit 6 (Day 15)</time_frame>
        <population>Intent to Treat - All subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 1% Ophthalmic Suspension</title>
            <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
            <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 15</title>
          <description>The difference in mean changes from BL in AC cell count grade at Day 15 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.
Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.
Anterior Chamber Cells 0 = No cells seen
= 1 - 5 cells
= 6 - 15 cells
= 16 - 30 cells
= greater than 30 cells</description>
          <population>Intent to Treat - All subjects randomized</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.84"/>
                    <measurement group_id="O2" value="-1.6" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0169</p_value>
            <p_value_desc>P-values have no inferential value for post hoc evaluations.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Without adjustments for any covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Estimated Value is the between-group difference for change from BL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time a subjects signed the informed consent until they exited the study at the end of Visit 7 (up to 18 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>KPI-121 1% Ophthalmic Suspension</title>
          <description>KPI-121 1% Ophthalmic Suspension dosed BID</description>
        </group>
        <group group_id="E2">
          <title>Vehicle of KPI-121 1% Ophthalmic Suspension</title>
          <description>Vehicle of KPI-121 1% Ophthalmic Suspension dosed BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>erebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instilation site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No submission for publication or public disclosure will be made by the PI until after the publication of the results of the multi-center clinical trial by the Sponsor. Thereafter, PI shall provide KALA with an advance copy of any proposed publication or public disclosure at least sixty (60) days prior to the planned date of submission or disclosure and KALA shall have forty-five (45) days from the date of its receipt to recommend changes.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head, Clinical Operations</name_or_title>
      <organization>Kala Pharmaceuticals, Inc.</organization>
      <phone>781-996-5252</phone>
      <email>Results005@kalarx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

